Molecular Biology Resources, Inc.

Nucleus Biologics | May 27, 2020

Nucleus Biologics, a leader in precision cell culture, today announced the availability of NB-Lux™, an online configuration and ordering platform for cell culture media. Designed for developers of cell therapies, NB-Lux™ speeds formulation development by providing real time pricing for cGMP grade media in lot sizes from two liters to 2000 liters.Media is a critical component in the production of cell therapies. During development, companies iteratively test multiple formulation...

Connecticut Biotech | August 14, 2020

Connecticut Biotech, a new innovative start-up company, is announcing the launch of its Secure Fit 3D-printed face mask frame. The mask frames are an exoskeleton worn outside of a traditional surgical mask, providing enhanced efficacy in protection against COVID-19 and other airborne pathogens. Secure Fit is a reusable, reliable device designed to make day-to-day interactions safer for users.In partnership with the University of Connecticut and under the leadership of surgeon-scientist Dr....

MedTech

Bionaut Labs | November 29, 2022

Bionaut Labs, the company that uses microscale robots to revolutionize the treatment of central nervous system diseases and disorders, announced $43.2M in a Series B round of financing led by Khosla Ventures, bringing the company’s total financing raised to date to $63.2 million. Also participating in the round are new investors Deep Insight, OurCrowd, PSPRS, Sixty Degree Capital, Dolby Family Ventures, GISEV Family Ventures, What if Ventures, Tintah Grace and Gaingels, along with all exis...

Industrial Impact

Harbour BioMed | February 28, 2022

Harbour BioMed announced that, it has been approved by the Institutional Review Boards to commence phase I trial of its B7H4x4-1BB bispecific antibody in Australia. This study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of HBM7008 in patients with solid tumors. HBM7008 is generated from our unique and innovative HBICE® platform. It targets Tumor Associated Antigen mediated crosslinking T cell activation t...